Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2018 Filed May 10, 2018 01:19 UTC |
Tansey Casey MDirector · 10% owner
|
ConversionCommon Stock | 389,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031863 · a4.xml · nonDerivative · entry 2 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 750,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1855 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:19 UTC |
Tansey Casey MDirector · 10% owner
|
ConversionCommon Stock | 360,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031863 · a4.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 360,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F4 · ownership.nature: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Mead Dana G Jr.Director
|
PurchaseCommon Stock | 20,000 | $16.00 | $320,000.00 |
DisclosureSEC source: 0001104659-18-031862 · a4.xml · nonDerivative · entry 1 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionSeries F Convertible Preferred Stock · Derivative | 53,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · derivative · entry 6 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionSeries E Convertible Preferred Stock · Derivative | 4,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · derivative · entry 5 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.exercise_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. F2 · derivative.expiration_date: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionSeries D Convertible Preferred Stock · Derivative | 46,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · derivative · entry 4 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,026 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionCommon Stock | 8,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · nonDerivative · entry 3 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionCommon Stock | 811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · nonDerivative · entry 2 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
ConversionCommon Stock | 7,026 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · nonDerivative · entry 1 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Erony JoyceDirector · 10% owner
|
ConversionSeries F Convertible Preferred Stock · Derivative | 9,124,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031860 · a4.xml · derivative · entry 3 Erony Joyce · CIK 0001459212 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,372,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2 · ownership.nature: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Erony JoyceDirector · 10% owner
|
PurchaseCommon Stock | 125,000 | $16.00 | $2,000,000.00 |
DisclosureSEC source: 0001104659-18-031860 · a4.xml · nonDerivative · entry 2 Erony Joyce · CIK 0001459212 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,497,043 F2 · ownership.nature: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:16 UTC |
Erony JoyceDirector · 10% owner
|
ConversionCommon Stock | 1,372,043 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031860 · a4.xml · nonDerivative · entry 1 Erony Joyce · CIK 0001459212 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,372,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F2 · ownership.nature: These shares are held of record by Amzak Health Investors, LLC ("Amzak Health"). Joyce Erony, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:41 UTC |
Herbert Timothy P.Director · CEO and President
|
PurchaseCommon Stock | 350 | $16.00 | $5,600.00 |
DisclosureSEC source: 0001104659-18-031848 · a4.xml · nonDerivative · entry 1 Herbert Timothy P. · CIK 0001737136 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 350 Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:41 UTC |
Jandrich StevenChief Comp Off & VP, Human Res
|
PurchaseCommon Stock | 350 | $16.00 | $5,600.00 |
DisclosureSEC source: 0001104659-18-031847 · a4.xml · nonDerivative · entry 3 Jandrich Steven · CIK 0001737203 · Chief Comp Off & VP, Human Res 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 350 Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:41 UTC |
Jandrich StevenChief Comp Off & VP, Human Res
|
PurchaseCommon Stock | 350 | $16.00 | $5,600.00 |
DisclosureSEC source: 0001104659-18-031847 · a4.xml · nonDerivative · entry 2 Jandrich Steven · CIK 0001737203 · Chief Comp Off & VP, Human Res 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 350 Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:41 UTC |
Jandrich StevenChief Comp Off & VP, Human Res
|
PurchaseCommon Stock | 1,350 | $16.00 | $21,600.00 |
DisclosureSEC source: 0001104659-18-031847 · a4.xml · nonDerivative · entry 1 Jandrich Steven · CIK 0001737203 · Chief Comp Off & VP, Human Res 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350 Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:40 UTC |
Buchholz RichardChief Financial Officer
|
PurchaseCommon Stock | 4,750 | $16.00 | $76,000.00 |
DisclosureSEC source: 0001104659-18-031846 · a4.xml · nonDerivative · entry 1 Buchholz Richard · CIK 0001737133 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Read SEC document |
| May 07, 2018 Filed May 10, 2018 00:40 UTC |
Ban RandySenior VP, Sales and Marketing
|
PurchaseCommon Stock | 900 | $16.00 | $14,400.00 |
DisclosureSEC source: 0001104659-18-031843 · a4.xml · nonDerivative · entry 1 Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,974 Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC |
JOHNSON & JOHNSON10% owner
|
ConversionSeries F Preferred Stock · Derivative | 248,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 37,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.exercise_price: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F1 · derivative.exercise_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · derivative.underlying_shares: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC |
JOHNSON & JOHNSON10% owner
|
ConversionSeries E Preferred Stock · Derivative | 1,145,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 0 Underlying: Common Stock · 197,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.exercise_price: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F1 · derivative.exercise_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.underlying_shares: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC |
JOHNSON & JOHNSON10% owner
|
ConversionCommon Stock | 37,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 235,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3 · price: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:50 UTC |
JOHNSON & JOHNSON10% owner
|
ConversionCommon Stock | 197,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-18-000335 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Johnson & Johnson Innovation - JJDC, Inc. · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Innovation - JJDC, Inc. Disclosed balance after: 197,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2 · price: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4 · ownership.nature: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:46 UTC |
NELSON MARILYN CDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031876 · a4.xml · derivative · entry 14 NELSON MARILYN C · CIK 0001199894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:22 UTC |
Khuong Chau QuangDirector · 10% owner
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031869 · a4.xml · derivative · entry 6 Khuong Chau Quang · CIK 0001609405 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:21 UTC |
Jain Mudit K.Director · 10% owner
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031868 · a4.xml · derivative · entry 11 Jain Mudit K. · CIK 0001584404 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:19 UTC |
mcCormick ShawnDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031865 · a4.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:19 UTC |
Tansey Casey MDirector · 10% owner
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031863 · a4.xml · derivative · entry 14 Tansey Casey M · CIK 0001474322 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:16 UTC |
Mead Dana G Jr.Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031862 · a4.xml · derivative · entry 2 Mead Dana G Jr. · CIK 0001222358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:16 UTC |
Griffin Jerry CDirector
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031861 · a4.xml · derivative · entry 7 Griffin Jerry C · CIK 0001327953 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| January 22, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 20,905 | $54.00 | $1,128,790.56 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 6 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 906,934 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.07 to $55.10. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 18, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 29,204 | $55.32 | $1,615,644.13 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 5 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 927,839 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $56.685. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 18, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 35,616 | $54.60 | $1,944,608.67 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 4 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 957,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.58 to $55.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 17, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 54,384 | $54.08 | $2,941,075.84 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 3 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 992,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.25 to $55.12. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 17, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 90,000 | $53.86 | $4,847,454.00 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 2 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,047,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $55.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 17, 2018 Filed Jan 22, 2019 23:31 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 59,296 | $52.66 | $3,122,640.02 |
DisclosureSEC source: 0001213900-19-001071 · ownership.xml · nonDerivative · entry 1 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,137,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $53.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 16, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 67,432 | $50.13 | $3,380,608.92 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 6 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,196,339 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $51.26. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 16, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 30,704 | $50.83 | $1,560,546.15 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 5 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,263,771 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.455 to $51.435. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 15, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 22,568 | $49.27 | $1,111,889.25 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 4 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,294,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.945 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 15, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 90,000 | $48.82 | $4,393,584.00 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 3 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,317,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $49.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 15, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 2,000 | $48.03 | $96,053.80 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 2 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,407,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $48.37. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| January 14, 2018 Filed Jan 16, 2019 23:49 UTC |
Erony JoyceDirector
|
SaleCommon Stock | 88,000 | $48.69 | $4,284,420.80 |
DisclosureSEC source: 0001213900-19-000817 · ownership.xml · nonDerivative · entry 1 Erony Joyce · CIK 0001459212 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,409,043 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.515 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein. Read SEC document |
| May 02, 2015 Filed May 10, 2018 01:16 UTC |
Erony JoyceDirector · 10% owner
|
GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031860 · a4.xml · derivative · entry 4 Erony Joyce · CIK 0001459212 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F3 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.